argenx (ARGX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed argenx (ARGX) over the past year, gaining 363.7% versus a gain of 2.5%. Over five years, ARGX leads with a +178.7% price change compared with +34.8% for TWST. argenx is the larger company by market cap ($50.93 billion vs $10.80 billion), about 4.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | TWST |
|---|---|---|
| Share price | $809.94 | $162.85 |
| Market cap | $50.93B | $10.80B |
| 1-day change | -1.06% | +7.10% |
| YTD return | -2.65% | +379.35% |
| 1-year return | +2.46% | +363.71% |
| 5-year return | +178.69% | +34.80% |
| P/E ratio (TTM) | 30.87 | — |
| Forward P/E | 23.33 | — |
| EPS (TTM) | $26.24 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.57M |
| Revenue growth (YoY) | — | +20.32% |
| Net income (latest FY) | $1.29B | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | — | -36.18% |
| Net margin | — | -20.63% |
| 52-week high | $1,072.75 | $219.71 |
| 52-week low | $661.85 | $23.30 |
| Distance from 52-week high | -24.50% | -25.88% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +44.70% | -7.69% |
| Average volume | 317.26K | 2.04M |
| Shares outstanding | 62.89M | 66.30M |
| Employees | 1,863 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 4.7 times larger than Twist Bioscience by market value ($50.93B vs $10.80B).
- TWST has outperformed ARGX by 361.2 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
ARGX vs TWST FAQ
Which is bigger, argenx or Twist Bioscience?
argenx (ARGX) is larger, with a market capitalization of $50.93B compared with $10.80B for Twist Bioscience (TWST).
Which stock has performed better over the past year, ARGX or TWST?
TWST returned +363.71% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.